For additional information about a press release, please contact:

 

Bridget Kimmel
Johnson & Johnson Communications
215-688-6033
Email: bkimmel@its.jnj.com

 

10/4/2017
Animas Corporation to Exit Insulin Pump Market

 

12/20/2016
OneTouch Vibe^™ Plus Insulin Pump Earns FDA Approval and Health Canada License and is First Pump Integrated with the Dexcom G5® Mobile Continuous Glucose Monitor

 

5/10/2016
Important UnitedHealthcare Coverage Update

 

1/11/2016
FDA Approves Animas^® Vibe^® Insulin Pump and Continuous Glucose Monitoring System For Use in Children

 

8/4/2015
Animas^® Collaborates with Tidepool to Integrate Insulin Pump Data to Open-Source Software Aiding Diabetes Management

 

12/1/2014
Animas^® Vibe™ Insulin Pump and Continuous Glucose Monitoring System Receives FDA Approval in United States

 

3/6/2014
Animas^® Vibe™ Insulin Pump and Dexcom G4™ PLATINUM CGM System is Now Approved for Children with Type 1 Diabetes in Europe

 

1/23/2014
Animas^® Vibe™ Insulin Pump with Latest Dexcom CGM Technology Now Available in Canada

 

6/21/2013
Animas^® Makes Progress in Development of a First-Generation Closed-Loop Insulin Delivery System With Study Participants Maintaining Safe Glucose Levels for Over 90 Percent of the Overnight Period

 

2/28/2013
Animas’ Development of a First-Generation Closed Loop Insulin Delivery System Progresses With Data Presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference

 

6/11/2012
Significant Step Forward for Millions with Type I Diabetes: Positive Results from Clinical Trials of a First-Generation Artificial Pancreas System

 

6/2/2011
Animas^® Vibe™, the First Integrated Offering from Animas^® Corporation and Dexcom, Inc., Receives European CE Mark Approval

 

5/11/2011
Animas^® and LifeScan Strengthen Strategic Focus to Better Serve People Living with Diabetes

 

1/13/2010
JDRF Forms Partnership with Animas^® to Develop First-Generation Automated System for Managing Type 1 Diabetes